Email
Print
Clostridium Vaccine (Animal Health) Market - Forecast(2024 - 2030)
Clostridium Vaccine (Animal Health) Market Overview
Clostridium Vaccine (Animal Health) Market Size is estimated to
reach $653.6 million by 2027 and it is poised to grow at a CAGR of 4.9% over the
forecast period of 2022-2027. The genus Clostridium is composed of a large
spectrum of Gram-positive, mesophilic and anaerobic species. It is found in the
soil and intestines of humans and animals. Vaccination plays a key role in the
protection of animals against clostridial diseases. The vaccinations are widely
utilized for a variety of species, including chicken, swine, ovine, bovine,
caprine and other animals. Animals are regularly immunized to protect them
from clostridial infections. To treat clostridial illnesses, a variety of
vaccinations, including single and combination vaccines, are available.
Toxoids, bacterins, or combinations of bacterins and toxoids make up the
combination vaccines.
Vaccines are made up by utilizing the natural capability of
biowarfare found in bacteria, as they produce antibiotics and other toxins to
kill closely related strains to reduce competition and that toxic protein known
as ‘bacteriocins’. Without vaccination
alteration in gut microbiota in animal lead to fatal infection and an increased
rate of mortality. To prevent mortality of livestock, to reduce chances of
infections and to minimize loss vaccination for clostridium if preferred. Owing
to such a need for vaccination global key market players continuously working
for developing new treatments for biowarfare to reduce clostridium infections
in bovine, ovine, caprine, Swine and Poultry. For instance, in March 2022, the vaccine for Pfizer Clostrodial Difficile in the phase 3 clover trial
showed a strong potential effect in reducing the duration and severity of the disease based on secondary endpoints. Such growing research and innovation and rising
demand for biodefence vaccines for animal health and to reduce the chance of
biowarfare fuel growth of the Clostridium Vaccine (Animal Health) industry over
the forecast period 2022-2027.
Clostridium Vaccine (Animal Health) Market Report Coverage
The report: “Clostridium Vaccine (Animal Health) Market Forecast
(2022-2027)", by Industry ARC covers an in-depth analysis of the following
segments in the Clostridium Vaccine (Animal Health) Market.
Key Takeaways
- Geographically, North America held a dominant market share in the year 2021, owing to the growing awareness about clostridium infection in animal health and commercial livestock and poultry production fueling the growth of the Clostridium Vaccine (Animal Health) Market Size.
- The Clostridium Vaccine (Animal Health) Market is predicted to increase owing to the increasing prevalence of clostridium-related disease and chances of zoonotic transmission from animal to human.
- However, the high storage cost of vaccines may limit the growth of the Clostridium Vaccine (Animal Health) Market over the forecast period 2022-2027.
- A detailed analysis of strengths, weaknesses, opportunities and threats will be provided in the Clostridium Vaccine (Animal Health) Market Report.
Clostridium Vaccine (Animal Health) Market: Market Share (%) by region, 2021
Clostridium Vaccine (Animal Health) Market Segment Analysis - by Animal Type
Clostridium Vaccine (Animal Health) Market based on animal type
can be further segmented into Bovine, Ovine, Caprine, Swine and Poultry. The Swine segment held a dominant market share in
the year 2021. This is owing to the growing demand for pork and the high
possibility of swine getting infected with clostridium. Also, the European
Society of Clinical Microbiology and Infectious Diseases found that Clostridium
Difficile zoonotic transmission is detected from infected swine to humans,
as a research study by Dr. Semeh Bejaoui and colleagues from the University of
Copenhagen and Statens Serum Institute in Denmark, in April 2022. Such chances
of zoonotic transmission and growing demand for pork create the need for a Clostridium Vaccine in swine and drive the growth of the Clostridium Vaccine
(Animal Health) Market Share.
However, the Poultry segment is
estimated to grow with the fastest CAGR rate of 5.7% over the forecast period
2022-2027. This is owing to the high risk of clostridium infections and the rate of
infection in poultry. Infections with Clostridium perfringens in poultry can
appear as subclinical infections or as acute clinical infections. The acute
form of the illness increases broiler flock mortality, which can result in
large losses of up to 1% per day and fatality rates as high as 50%. Also,
according to a research article published in Multidisciplinary Digital Publishing
Institute (MDPI), in May 2022, showed that the biodefence vaccine from Clostridium perfringens
is useful for necrotic enteritis (NE) in chickens. Such a high mortality rate in
poultry and the number of vaccines available fuel the growth of the Clostridium Vaccine (Animal Health) Market Share over the
forecast period 2022-2027.
Clostridium Vaccine (Animal Health) Market Segment Analysis - by Disease
Clostridium Vaccine (Animal Health) Market based on the disease
can be further segmented into Swine Pneumonia, Avian Influenza, Rabies,
Coccidiosis, Brucellosis and Canine Distemper. The Swine Pneumonia segment
held a dominant market share in the year 2021. The swine are mostly susceptible
to infectious disease and most susceptible to swine fever & swine
pneumonia as it is highly contagious. According to a research paper published in
National Center for Biotechnology Information (NCBI), in December 2021, swine
pneumonia is found in 73.1% of pigs from a total of 108 pigs. Such a high prevalence
of Swine pneumonia and the positive impact of the Clostridium Vaccine on swine
pneumonia drive the growth of the Clostridium Vaccine (Animal Health) Market
Share.
However, Avian Influenza is estimated
to grow with the fastest CAGR rate of 5.1% over the forecast period 2022-2027.
Avian influenza commonly known as bird flu is consist large family of influenza
viruses that affect humans and birds and mostly seen in birds. In July 2022, the
U.S. Department of Agriculture (USDA) reported 40.09 M birds in 36 U.S. states
to be infected with highly pathogenic avian influenza (HPAI). Also, as per the
World Health Organisation (WHO) and as of 31 March 2022, a total of 239 cases of
human infection with avian influenza A(H5N1) virus have been reported from four
countries within the Western Pacific Region since January 2003. Such high cases
of infections in birds create a threat to the poultry industry and surge demand
for vaccination. Such growing demand for vaccination owing to avian influenza
fuels the growth of the Clostridium Vaccine (Animal Health) Market Share over the
forecast period 2022-2027.
Clostridium Vaccine (Animal Health) Market Segment Analysis - by Geography
The Clostridium Vaccine (Animal Health) Market based on Geography
can be further segmented into North America, Europe, Asia-Pacific, South
America and the Rest of the World. North America held a dominant market share
of 36% in the year 2021. This is the result of the increasing demand for meat and
meat products and the low availability of land to manage livestock and birds. Also,
high awareness about zoonotic disease surges demands for biodefence vaccines. Also,
the growing risk of zoonotic transmission and biowarfare create demand for new
drugs in the market. In May 2022, Clinical Trials studied the safety and immunogenicity
of GSK's Clostridium Difficile Vaccine 2904545A on adults. Clostridium
infection causes severe economic losses in livestock and poultry industries in
this region. According to the Centers for Disease Control and Prevention (CDC)
estimates these bacteria cause nearly 1 million illnesses in the United States
every year. For animal husbandry, necrotizing enteritis caused by C.
perfringens can cost the global livestock industry between $2 billion and $6
billion per year. Such a high burden of clostridium-related disease drives the
growth of the Clostridium Vaccine (Animal Health) Market Size.
Furthermore, Asia-Pacific is estimated to grow with the fastest CAGR over the forecast period 2022-2027. This is owing to the high prevalence of clostridium-related disease in Asia-Pacific. According to a research article published in the Frontiers in July 2022, out of 160 bovine samples collected from four major bovine-producing regions in the Punjab Province of Pakistan, 33 isolates showed a positive result for C. perfringens. Such a high prevalence of clostridium infections in underdeveloped countries of Asia-Pacific creates demand for biodefence vaccines which fuels the growth of the Clostridium Vaccine (Animal Health) Market Size over the forecast period 2022-2027.
Clostridium Vaccine (Animal Health) Market Drivers:
High Rate of Clostridium Infection and Mortality in Animals Drive Market Growth.
Clostridium bacteria are commonly found in the intestine
of many organisms but any alteration of gut microbiota leads to fatal infection
from this organism. It is mostly reported in chicken, swine, ovine, bovine, caprine and other animals. The
presence of clostridium is associated with diarrhea in infected horses. Recently,
C. difficile has been associated with the so-called duodenitis-proximal
jejunitis (DPJ) syndrome, a sporadic gastrointestinal process for which a
specific cause is largely unknown. As per a research paper published by National
Center for Biotechnology Information (NCBI) in 2020, Clostridium perfringens have
the potential to produce up to 16 different toxins. the large clostridial
cytotoxins consist of single peptide chains averaging about 250,000 MW. Such a combination
of different types of toxins and high risk of mortality in chicken, swine, ovine, bovine,
caprine and other animals surge demand for veterinary Clostridium Vaccine and
propel the growth of the Clostridium Vaccine (Animal Health) Industry over the forecast period 2022-2027.
The Broad Range of Coverage for Various Disease from Clostridium Vaccine is Driving the Market Growth.
The Clostridium Vaccine is capable to provide immunity against diseases
such as tetanus, black disease, pulpy kidney (enterotoxaemia) and blackleg. For
instance, enterotoxaemia is caused by Clostridium perfringens type D. In
October 2021, the Department of Animal Husbandry and Veterinary Services
(AH&VS), Bengaluru reported the death of 35 sheep and an investigation
found a strain of the Clostridium Perfringens in the gastrointestinal tract. According
to the research paper published in the National Center for Biotechnology
Information (NCBI), in March 2022 it is reported in Brazil, China, Italy,
Pakistan, Spain, Saudi Arabia, South Africa and the USA. Owing to such a high
prevalence of disease and the impact of the Clostridium vaccine drive the growth of the
Clostridium Vaccine (Animal Health) Industry over the forecast period
2022-2027.
Clostridium Vaccine (Animal Health) Market Challenges
High Storage Cost for Vaccines is Hampering Market Growth
Vaccines consist of live or weekend strains of bacteria that
trigger immunity. To store and transport vaccines it needs cold storage system.
To keep the vaccination effective, the storage temperature needs to be
carefully monitored and regulated. Measles and DTP vaccines, for example, are
more sensitive to heat, but Heb B and Hib are more vulnerable to freezing. If
the vaccines are not stored correctly, that could impact the vaccine’s efficacy
or even lead to contamination. Ultra-cold freezers cost around $10,000 each,
such a high cost of storage restricts the supply of vaccines in rural areas and hamper
the growth of the Clostridium Vaccine (Animal Health) Industry over the
forecast period 2022-2027.
Clostridium Vaccine (Animal Health) Industry Outlook
Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Clostridium Vaccine (Animal Health) Market. The top 10 companies in the Clostridium Vaccine (Animal Health) Market are:
- Bayer AG
- Bimeda Inc.
- C.H. Boehringer Sohn Ko. KG
- Ceva
- Elanco Animal Health Incorporated
- Merck Animal Health
- Sanofi S.A.
- Virbac
- Zoetis Inc.
- Colorado Serum Company
Recent Developments
- In March 2022, The Bimeda announced the establishment of a new business unit in Europe. With headquarter in Odense, Denmark and will supply Bimeda products to the wider Nordic region, including Denmark, Sweden, Finland, Norway and Iceland.
- In June 2021, Bayer and Cadila extended their period of the joint venture for three years, effective from June 2021. The companies had entered into an agreement on January 28, 2011, to set up the joint venture Bayer Zydus Pharma for the sales and marketing of pharmaceutical products in India, with headquarters in Mumbai. The Partnership in this joint venture with channeling the core strengths of both Zydus and Bayer for the benefit of the patients of both companies.
- In May 2021, Bimeda announced the acquisition of AquaTactics Fish Health, the company provides fish health services and develops, manufactures and sells bespoke fish vaccines to its fish farm and stock enhancement clients across the USA. With this strategic investment, Bimeda enters the Aquaculture space, a rapidly growing animal healthcare segment.
Relevant Titles
Report Code: HCR 0058
Report Code: HCR 0422
Report Code: HCR 0648